Skip to content
Menu
REDD-Monitor
  • Start here
  • About REDD-Monitor
  • REDD: An introduction
  • Contact
REDD-Monitor

Red flags: Radley Ventures Nominees, part of the Thorn Medical network, is selling shares in Med Cell Plc, a Liverpool-based firm linked to stem cell company Med Cell Bahamas

Posted on 27 September 201822 February 2023

A company called Radley Ventures Nominees is involved in selling shares in Med Cell Plc, a UK registered company linked to a stem cell research company in the Bahamas. REDD-Monitor has seen a copy of Radley Ventures Nominees’ “Confidential Private Placement Agreement”. Needless to say, this so-called “investment” raises plenty of red flags.

red flagRadley Ventures Nominees is not registered with the Financial Conduct Authority. On its website, the FCA writes, “We strongly suggest you avoid dealing with unauthorised firms.”

On the first page of Radley Ventures Nominees’ “Confidential Private Placement Agreement” is the following statement:

The contents of this private placement agreement have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this private placement agreement for the purpose of engaging in any investment activity may expose an individual to significant risk of losing some or all of such investment.

red flagRadley Ventures is part of the Thorn Medical network of companies. One of the directors of Radley Ventures Nominees is Gordon McIvor Wilson. He was also a director of Thorn Medical, until he resigned in May 2017. Thorn Medical is currently in liquidation.

Before going bust, Thorn Medical had a strange, but colourful history. In January 2016, the company announced that it was planning a £350 million listing on the London Stock Exchange. That never happened. Neither did a listing on the USA’s Nasdaq. None of the company’s plans came to anything.

Radley Ventures NomineesTwo companies are listed on the Companies House website as having significant control in Med Cell Plc: Conformo Ltd; and Kurdam Ltd. These two companies were the biggest shareholders in Thorn Medical.

Jack Kaye, the man behind Thorn Medical, is a director of Conformo and Kurdam.

Radley Ventures NomineesRadley Ventures Nominees was registered at Companies House in April 2013. Until March 2015, the company’s names was Astroway Projects Ltd. The nature of the company’s business is listed as, “Retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) not elsewhere classified” and “Other human health activities”.

The registered office address is Savoy House, Savoy Circus, London, W3 7DA. Several hundred other companies are also registered at this address. Here it is on Google maps:

Radley Ventures Nominees

Wem & Co is a firm of chartered accountants.

Radley Ventures NomineesA company called Radley Ventures was registered at Companies House in December 2016. Gordon McIvor Wilson was a director until he resigned in October 2017. The company changed its name to Kyrix Medical Projects in October 2017. The company was dissolved via voluntary strike-off in May 2018.

Another company, called Radley Pharma, was registered in July 2007. Gordon McIvor Wilson has been a director since September 2011. The company’s registered office is also Savoy House. At the end of 2016, the company had fixed assets of £998 and £1,479 in the bank. The company has no employees.

Radley Ventures NomineesMed Cell Plc was registered in March 2018. The company’s registered address is 48-52, Penny Lane, Mossley Hill, Liverpool, England, L18 1DG. Hundreds of other companies are registered at the same address. It’s another firm of chartered accountants:

Radley Ventures Nominees

Radley Ventures NomineesOne of Med Cell Plc’s directors, Peter Kellner, is also director of a company called Med Cell Bahamas, registered in the Bahamas. (There are echoes here of Thorn Medical’s involvement with a stem cell company called Okyanos. You can read more about that in the comments following this November 2016 post on REDD-Monitor – including a response from Thorn Medical’s director, Jack Kaye.)

Kellner was also chairman and CEO of a Swiss company called Med Cell Europe, from January 2010 to December 2016, according to his LinkedIn page. The company’s website consists of the following announcement:

Radley Ventures Nominees

An archived version of the website is available here. An investor presentation about Med Cell Bahamas explains that the law on stem cell treatments in Switzerland was changed in 2015. So Med Cell moved to the Bahamas.

According to the investor presentation, Med Cell Bahamas is owned by Med Cell International, which in turn is owned by its founders: Steven Kellner (50%), Peter Kellner (25%), and Miriam Reif (25%). Med Cell International was registered in Delaware in December 2017.

In August 2016, the Bahamas National Stem Cell Ethics Committee granted Med Cell Bahamas provisional approval to conduct stem cell research and build a laboratory. One year later, the Bahamas Journal reported that, “An initial $4 million was invested for the attainment of laboratory and storage equipment as well as the recruitment of some seven to 10 employees.”

But there are no photographs of the laboratory building on Med Cell Bahamas’ website. On the website, the company claims to have a scientific advisory board, but it does not give the names of any of the people on the board. In an “executive summary” Kellner writes that,

The company currently has over 475 clients worldwide and is now posed to establish its global headquarters and ‘centre-of-excellence’ with a stem cell laboratory and therapy centre in the Bahamas.

Radley Ventures NomineesKellner has posted a brochure advertising Med Cell Bahamas on SlideShare. It was posted on 17 January 2017. The brochure gives the impression that the laboratory is completed:

In our laboratory intensive research takes place in the ongoing development of secure and efficient processes for the treatment and cryopreservation of adult stem cells from adipose tissue.

The brochure includes this photograph – which certainly gives the impression that the laboratory is finished:

Radley Ventures Nominees

Unfortunately, the photograph was lifted from swiss-medicine.ru – a website about health care in Switzerland for Russians.

Radley Ventures NomineesThe last page of Med Cell Bahamas’ investor presentation states “For further information, application form or subscription agreement please contact: David Campbell or your introducer.” Campbell is a director of Med Cell Plc.

Campbell has also been a director of two “Thorn” companies: Thorn Ventures Limited, and Thorn Operations Limited, although he was director of the latter for only one day.

Campbell has some experience of investments in the Bahamas. He is also a director of a company called JV Investments (UK) Limited, a company that encouraged people to invest in plots in an “Eco Village Development” on Long Island, Bahamas.

According to a June 2016 article in Tribune 242, Campbell was the developer of the project. He “splits his time between Canada and Switzerland”, the article notes, adding that,

The somewhat mysterious Eco Village Bahamas has its own website, but it is unclear whether the project has obtained the necessary permits and approvals from the Government to proceed.

John Brier and three other investors ended up taking out a legal case in North Florida against Keith De Cay, one of people involved in the project in the Bahamas. Tribune 242 reported that De Cay admitted “that the land sales to Mr Brier’s group were illegal because the lots were not in an approved subdivision, as required by the Planning and Subdivisions Act”.

Brier and the other investors won their case and received their investments back from the landowner, Billy Wayne Davis, a man who Tribune 242 describes as having had a “long and colourful career in real estate sales”.

Radley Ventures NomineesRadley Ventures Nominees is not selling shares in Med Cell Bahamas, or in Med Cell International, but in a company called Med Cell Plc, which has a registered office in a firm of accountants in Liverpool.

High risk doesn’t come close to describing these shares as an investment.

The Financial Conduct Authority has some good advice on its website for people who have invested in these sort of shares:

If you are concerned about an investment, you should stop sending money to the firm and individuals involved. If you have given them your bank account details, tell your bank immediately.

If you are contacted by Radley Ventures Nominees, or any other company selling shares in Med Cell Plc, put down the phone and report the call to Action Fraud and the Financial Conduct Authority.
 

18 thoughts on “Red flags: Radley Ventures Nominees, part of the Thorn Medical network, is selling shares in Med Cell Plc, a Liverpool-based firm linked to stem cell company Med Cell Bahamas”

  1. Andrew Wildman says:
    27 September 2018 at 11:35 pm

    Scam written all over it

  2. Gerfried von Kynhoff says:
    27 September 2018 at 11:53 pm

    I’m rather worried now, as I wonder how this all will effect the Price of MedCell shares?

  3. Chris Lang says:
    28 September 2018 at 9:45 am

    @Gerfried von Kynhoff – I assume you bought shares in Med Cell. Would you mind answering a few questions about how, and why, you decided to invest:

    – How did you hear about this “investment” opportunity?
    – Which company told you about Med Cell?
    – Why did you decide to invest in such a high risk investment?

  4. Hilda says:
    28 September 2018 at 8:43 pm

    My partner is owed 800,000 shares – been waiting for 6yrs for them to list

  5. kAPUR.SHAH says:
    30 September 2018 at 10:31 pm

    i am really impressed.with information

  6. Brian De-Honri says:
    24 October 2018 at 11:37 pm

    I invested in Thorn Medical who were then taken over by Technicity and finally MedCell. I have been contacted and asked if I want to sell my shares in MedCell. Should I be worried?

  7. NAME WITHHELD says:
    26 October 2018 at 4:53 pm

    I found your Red Flag when doing due dilligence into Radley Ventures and Med cel PLC

    I was contacted by cold call by Ray Singh of Radley Ventures followed-up by an e-mail from Gordon McIvor Wilson. The story was of Med Cel Plc planning to float on NASDAQ North in January with a listing of company doing Stem Cel Reasearch and having already established a frozen Stem Cell Bank which some rich and famous had already donated their stem cells to should they need them in the future when technology uses these to combat diseases later. Also having other related products on the market and being expanding company via take-over.
    I said I would read their details as I like to review investment oportunities. They must have got my name from someone else in the high yield financial sector.
    The oportunityin this one was to get into this share offering at a discount price before floatation with discount shares now. Current Med Cel price being 1.80 but I have been offered discount via Gordoin Wilson of £1.40 per share for 1500 shares costing £2,100.00. Gordon Wilson having these discounterd shares available to him as a Director of both firms.
    Shares would be issued within ten days of payment. But only valuation at the moment is by them.
    These shares expected to rise significantly on floatation and company progress and as this type of medicine becomes more mainstream. They also hold shares in a Medical Canabis specialist company which is another area where expansion is expected to grow.
    They would introduce me to a choice of several suitable stock brokers who could deal the shares on NASDQ North when floated.
    I visted website http://www.medcell.health/thecompany and downloaded their fourth quartery Shareholder Newsletter.
    They plan to establish a Worldwide Centre of Excelence in Bahamas and have an extensive piece of land available.

    The Newsletter 04 says that there are 83,593,130 Ordinary Shares of Med Cel in circulation. (Nominal value 0.01 Euro each)
    Preference shares (presumably held by a privalidged few have 100 times voting rights in the company (That is usually so that the founders can keep control, and in my experience typical in dodgy deals.)

    Your Red Flag has discouraged me enough to decide not to complete the application or invest with them.

    I have all my written correspondence with them on file and am willing to send it to the Anti-Fraud police if required.

  8. Lady Gil Marston-Haynes says:
    18 February 2019 at 12:59 pm

    Has anybody looked at Med Cell recently, with Jack Kaye holding 25% but under 50% thru his own name and various companies. 54m shares out of 123m shares so we have been advised.
    They keep saying they will be listed since last May and finally they said Nasdaq North will not accept them so now its the Vienna Borse but they have to sell over €100 on their bond which we have been told has been done and now they want both to be listed simultaneously on the Vienna Borse but are waiting to be listed, but we have been here before,
    It smells like a fish, it looks like a fish and by golly it is a fish!!

  9. Frank Kinlan says:
    7 March 2019 at 4:51 am

    This does not look good.

    https://beta.companieshouse.gov.uk/company/11240560/filing-history

  10. Chris Lang says:
    7 March 2019 at 9:10 am

    @Frank Kinlan – I’m not sure which specific bit of this you think doesn’t look good – here’s a screenshot of the Companies House filing history taken today:

  11. Frank Kinlan says:
    8 March 2019 at 10:00 pm

    The Medcell investor pages and links have been deleted and now we are left with only links to an unauthorised facility in the Bahamas, which would appear to be their only asset other than a filing cabbinet. I was told by a certain Mike French that his commission on a £40K 2 block transaction wouldn’t fill his Bentley. I held 1 block at the time.

  12. Iceman says:
    9 March 2019 at 1:34 am

    Sorry, who is Mike French and where did you get your shares from?

  13. Chris Lang says:
    9 March 2019 at 11:37 am

    @Iceman – Good question.

    @Frank Kinlan – You write that, “The Medcell investor pages and links have been deleted”. Which Med Cell investor pages? Can you provide the web address, please? Thanks.

  14. Lorin Faptosu says:
    25 October 2019 at 12:36 am

    I bought some “shares” worth a few thousand pounds back in 2014 in Westhouse Medical which were “transferred” into Thorn Medical which were “transferred” into Teknisity which were “transferred” into Med Cell which are now about to be “transferred” into FOS a.s.o. I have already written off this “investment” but what I do not understand is that why do these thieves still bother to send us newsletters and offers to transfer from one fake company to another when they could simply give up any communication whatsoever, given that they already have my (and your) money.

  15. RJ Mead says:
    24 January 2020 at 8:35 pm

    I think people need to be very careful about putting things in writing. Opinions are not facts. And facts get muddled over the years. Be careful before posting anything or sending spurious emails to berate people. Take it up via the correct channels if need be but be very wary about posting on the WWW where it will undoubtedly be repeated at some point in a public forum where you will need to justify yourself.

  16. James D. says:
    24 February 2020 at 6:06 pm

    I purchased Thorn Medical shares back in January 2015, on the promise they were about to list. As we know this never happened. Then they switched to Tekinisity, via a share swap, then again to MedCell. Each time the number of shares I had halved.
    Last year I was contacted by MedCell claiming that the Teknisity shares were actually gifted to me, personally, by Jack Kaye. I checked all previous correspondence, and there was no mention of this at the time I accepted the share swap. I found this a bit strange, and therefore contacted Myers Clark, who were handled the Thorn Medical liquidation. When I told them about the so called gifting of shares, they knew nothing about it. I explained my situation, and asked them what happened to all the shareholder money that had been invested in Thorn, their answer was that they would also love to know where it went!
    Each time I have been offered a share swap I’ve tried to sell my shares, but there have been no takers, surprise, surprise.
    When I have called to speak to someone (Thorn, Teknisity, MedCell), I have always been told my shares were still worth approx. what I paid for them. During my most recent call, I was told MedCell was valued at £100m+.
    I rejected the latest swap to FOS, as it didn’t make sense, FOS were only valued at £5m.
    I’ve now received another letter regarding swapping my shares to Vendrove, and this time the offer is 1 Vendrove share for 20 MedCell shares.

    THESE GUYS SHOULD BE IN JAIL.

  17. Lana says:
    25 February 2020 at 9:10 pm

    Why should they be in jail? Your hysteria only serves to highlight your ignorance.
    The written word can never be erased.

  18. Dave says:
    7 June 2022 at 10:14 pm

    Kaye is somehow too slippery for the fca to pin down but he will get caught in the end. He’s bad news. He will undoubtedly go to prison at some point. He owes people money. He likes to think he’s very clever but he really isn’t. He’s a bully. He has an achilles heel like everyone.

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE!

Recent themes
30x30
Natural Climate Solutions
WWF's conservation scandals
Aviation and offsetting
Conservation Watch

Recent Comments

  • Ben on Response from Kurt Kaiser, Director of Compass Carbon: “Your article was of great concern to us”. And some questions for Kaiser from REDD-Monitor
  • James Mewa Kamaya on Papua New Guinea’s Forest Authority cancels Mayur Resources’ Kamula Doso REDD project
  • Benedikt von Butler on Switzerland’s offsetting deal with Peru excludes REDD. It will still not reduce emissions
  • Chris Ibe on Bar Works: The return of Renwick Haddow
  • Xindia on Bar Works: The return of Renwick Haddow

Recent Posts

  • REDD-Monitor is moving to Substack
  • REDD Project in Brazil Nut concessions in Madre de Dios, Peru finally started paying communities a decade after the project started. “I’m still lacking money,” says one community member
  • REDD-Monitor’s top ten posts in 2022
  • The harsh reality of 30×30: The EU is keen to allow extractivism in the 30×30 target – but not Indigenous Peoples’ territories
  • Human rights abuses against Indigenous Peoples and the proposed “30×30” target

Recent Comments

  • Ben on Response from Kurt Kaiser, Director of Compass Carbon: “Your article was of great concern to us”. And some questions for Kaiser from REDD-Monitor
  • James Mewa Kamaya on Papua New Guinea’s Forest Authority cancels Mayur Resources’ Kamula Doso REDD project
  • Benedikt von Butler on Switzerland’s offsetting deal with Peru excludes REDD. It will still not reduce emissions
  • Chris Ibe on Bar Works: The return of Renwick Haddow
  • Xindia on Bar Works: The return of Renwick Haddow

Issues and Organisations

30x30 AB 32 Andes Amazon Boiler rooms California Can REDD save ... ? Carbon accounting Carbon Credits Carbon Offsets CDM Conservation-Watch Conservation International COP21 Paris Cryptocurrency Deforestation EcoPlanet Bamboo Evictions FCPF Financing REDD Fossil fuels FSC Green Climate Fund Greenpeace Guest post Human rights ICAO Illegal logging Indigenous Peoples Natural Climate Solutions NGO statements Plantations R-M interview REDD and rights REDD in the news Risk RSPO-Watch Safeguards Sengwer The Nature Conservancy UN-REDD UNFCCC Verra World Bank WRM WWF

Countries

Australia Bolivia Brazil Cambodia Cameroon Canada China Colombia Congo Basin region Costa Rica DR Congo Ecuador El Salvador European Union France Gabon Germany Guyana Honduras India Indonesia Kenya Luxembourg Madagascar Malaysia Mexico Netherlands Nicaragua Norway Panama Papua New Guinea Paraguay Peru Republic of Congo Sierra Leone Spain Sweden Tanzania Thailand Uganda UK Uncategorized United Arab Emirates USA West Papua
©2025 REDD-Monitor | Powered by SuperbThemes!